title: Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication.
abstract: We were initially highly skeptical that differences in the concentrations of thimerosal in vaccines would have any effect on the incidence rate of neurodevelopmental disorders after childhood immunization. This study presents the first epidemiologic evidence, based upon tens of millions of doses of vaccine administered in the United States, that associates increasing thimerosal from vaccines with neurodevelopmental disorders. Specifically, an analysis of the Vaccine Adverse Events Reporting System (VAERS) database showed statistical increases in the incidence rate of autism (relative risk [RR] = 6.0), mental retardation (RR = 6.1), and speech disorders (RR = 2.2) after thimerosal-containing diphtheria, tetanus, and acellular pertussis (DTaP) vaccines in comparison with thimerosal-free DTaP vaccines. The male/female ratio indicated that autism (17) and speech disorders (2.3) were reported more in males than females after thimerosal-containing DTaP vaccines, whereas mental retardation (1.2) was more evenly reported among male and female vaccine recipients. Controls were employed to determine if biases were present in the data, but none were found. It was determined that overall adverse reactions were reported in similar-aged populations after thimerosal-containing DTaP (2.4 +/- 3.2 years old) and thimerosal-free DTaP (2.1 +/- 2.8 years old) vaccinations. Acute control adverse reactions such as deaths (RR = 1.0), vasculitis (RR = 1.2), seizures (RR = 1.6), ED visits (RR = 1.4), total adverse reactions (RR = 1.4), and gastroenteritis (RR = 1.1) were reported similarly after thimerosal-containing and thimerosal-free DTaP vaccines. An association between neurodevelopmental disorders and thimerosal-containing DTaP vaccines was found, but additional studies should be conducted to confirm and extend this study.
authors.affiliation: The Genetic Centers of America, Silver Spring, Maryland 20905, USA. mgeier@erols.com
authors.forename: Mark R
authors.initials: MR
authors.lastname: Geier
authors.forename: David A
authors.initials: DA
authors.lastname: Geier
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D002675:Child, Preschool; D016208:Databases, Factual; D002658:Developmental Disabilities / Q000139:chemically induced* / Q000453:epidemiology; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000009:adverse effects* / Q000737:chemistry; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000453:epidemiology; D011159:Population Surveillance; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects* / Q000737:chemistry; D018570:Risk Assessment; D013849:Thimerosal / Q000009:adverse effects* / Q000737:chemistry; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D011310:Preservatives, Pharmaceutical; D013849:Thimerosal